Joost J. M. Holthuis
Vorsitzender bei Crossbeta Biosciences BV
Ursprung des Netzwerks ersten Grades von Joost J. M. Holthuis
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Biogeneration Management BV
 Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.
14
| Subsidiary | Investment Managers | 14 |
Dr. Reddy's Research & Development BV
 Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands.
13
| Subsidiary | Pharmaceuticals: Major | 13 |
Cristal Delivery BV
 Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Crossbeta Biosciences BV
 Crossbeta Biosciences BV BiotechnologyHealth Technology Crossbeta Biosciences BV develops drug discovery programs in the area of misfolded protein diseases. It specializes in alzheimer's disease drug development and drug discovery platform services. The company was founded by Martijn Gebbink and Barend Bouma in 2005 and is headquartered in Utrecht, the Netherlands.
2
| Holding Company | Biotechnology | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Joost J. M. Holthuis
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| GALAPAGOS NV | Biotechnology | Director/Board Member | |
BMEYE BV
 BMEYE BV Electronic Equipment/InstrumentsElectronic Technology BMEYE BV operates as a non-invasive cardiovascular monitoring company. The firm manufactures and distributes non-invasive technology, hemodynamic monitoring equipment and related medical devices. It offers finger arterial pressure and cardiac output technologies. The company was founded in April 2005 and is headquartered in Amsterdam, the Netherlands. | Electronic Equipment/Instruments | Director/Board Member President Director/Board Member | |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investment Managers | Private Equity Investor | |
| SILENCE THERAPEUTICS PLC | Miscellaneous Commercial Services | Chairman Chairman | |
| FEEDBACK PLC | Packaged Software | Chairman Director/Board Member | |
| PHARMING GROUP N.V. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal Director/Board Member | |
Avantium Technologies BV
 Avantium Technologies BV Miscellaneous Commercial ServicesCommercial Services Avantium Technologies BV operates as chemical technology company. It offers a breeding ground for revolutionary renewable chemistry solutions. The firm specializes in innovations and technologies for catalytic research and development services and systems. The company was founded in February 2000 and is headquartered in Amsterdam, the Netherlands | Miscellaneous Commercial Services | Director/Board Member Chief Operating Officer | |
Morphochem AG
 Morphochem AG Miscellaneous Commercial ServicesCommercial Services Morphochem AG discovers and develops drugs. It focuses on finding therapeutic agents to treat cancer, anti-infectives, inflammation, metabolic disorders and infectious diseases, with particular emphasis on enzyme inhibitors. The company has developed an integrated chemical genomics drug discovery engine that it is applying in third party research programs and for building its own fully owned pipeline. Morphochem is headquartered in Munich, Germany. | Miscellaneous Commercial Services | Director/Board Member Chief Operating Officer | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
| University of Amsterdam | College/University | Graduate Degree Doctorate Degree Doctorate Degree Undergraduate Degree | |
Trinity Biosystems, Inc.
 Trinity Biosystems, Inc. Pharmaceuticals: MajorHealth Technology Trinity Biosystems, Inc. develops and formulates orally delivered bio-therapeutic macromolecules. It offers TriPex system, an approach to macromolecule delivery that works cooperatively with the natural physiology of the body. The system utilizes a specific and natural biological transport mechanism: a receptor-mediated transcellular transport pathway that allows passage through the mucosal epithelium and delivery of the therapeutic payload into the blood. The company was founded by Randall J. Mrsny on July 19, 2002 and is headquartered in Menlo Park, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Erasmus University Rotterdam | College/University | Graduate Degree Masters Business Admin Graduate Degree Doctorate Degree | |
| Delft University of Technology | College/University | Graduate Degree | |
| University of Utrecht | College/University | Graduate Degree Graduate Degree Graduate Degree Doctorate Degree Corporate Officer/Principal Graduate Degree Doctorate Degree | |
| University of Groningen | College/University | Doctorate Degree Graduate Degree | |
Polpharma Biologics Utrecht BV
 Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree | |
Stichting Publieke Private Samenwerking Versterking
 Stichting Publieke Private Samenwerking Versterking Investment Trusts/Mutual FundsMiscellaneous Stichting Mibiton promotes research, development, and entrepreneurship in the life sciences sector. The foundation is focused on biomedical sciences, chemistry, food, agricultural, and environmental technology. Stichting Mibiton was founded in 1994, formally called as Stichting Publieke Private Samenwerking Versterking van de Materiële Infrastructuur BioTechnologisch Onderzoek in Nederland and is based in The Hague, The Netherlands. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| AVANTIUM N.V. | Industrial Machinery | Director/Board Member Corporate Officer/Principal | |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Corporate Officer/Principal Chairman | |
Mckinsey & Co. /Amsterdam/
 Mckinsey & Co. /Amsterdam/ Miscellaneous Commercial ServicesCommercial Services Part of McKinsey & Co., Inc., Mckinsey & Co. /Amsterdam/ provides management consultancy services. The company is based in Amsterdam, Netherlands. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Weizmann UK
 Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | Miscellaneous Commercial Services | Director/Board Member | |
Neuravi Ltd.
 Neuravi Ltd. Medical SpecialtiesHealth Technology Neuravi Ltd. designs and develops medical devices for the treatment of acute stroke. Through its investment in the Neuravi Thromboembolic Initiative the company supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics to improve patient outcomes in stroke. Neuravi The company was founded by Mahmood K. Razav, Eamon Brady, John O'Shaughnessy and David Vale in 2009 and is headquartered in Galway, Ireland. | Medical Specialties | Director/Board Member | |
| Regiegroep Lsh | Director/Board Member | ||
Fast Forward Pharmaceuticals BV
 Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Medical Specialties | Chief Executive Officer | |
Mellon Medical BV
 Mellon Medical BV Medical SpecialtiesHealth Technology Mellon Medical BV manufactures and develops surgical suturing devices. The firm’s suturing device, the Switch, is designed for surgeons who perform the challenging operations and can easily be rotated in the hand because of its pencil-like shape. The company was founded in April 2013 by Mark Vrancken Peeters and is headquartered in Nijmegen, the Netherlands. | Medical Specialties | Director/Board Member Chairman Director/Board Member | |
| Stanford Graduate School of Business | College/University | Masters Business Admin Masters Business Admin | |
SynAffix BV
 SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Biotechnology | Director/Board Member | |
SurgVision BV
 SurgVision BV Medical SpecialtiesHealth Technology SurgVision BV provides optical imaging camera systems. It develops integrated optical imaging platforms, including camera, software and target specific tracer, for specific disease areas like breast cancer surgery. The company was founded by Vasilis Ntziachristos and Ton van den Hoven in 2011 and is headquartered in 't Harde, the Netherlands. | Medical Specialties | Director/Board Member Chairman | |
Confo Therapeutics NV
 Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Chief Executive Officer Director/Board Member | |
Escalier Biosciences BV
 Escalier Biosciences BV BiotechnologyHealth Technology Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands. | Biotechnology | Director/Board Member | |
Scenic Biotech BV
 Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Miscellaneous Commercial Services | Director/Board Member | |
| Merck Healthcare | Chief Operating Officer | ||
Genase Therapeutics BV
 Genase Therapeutics BV Pharmaceuticals: MajorHealth Technology Genase Therapeutics BV develops therapeutic products to treat solid tumors. The company is based in Oss, Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
TigaTx BV
 TigaTx BV Miscellaneous Commercial ServicesCommercial Services TigaTx BV is a Dutch company that specializes in research and development in the field of health nutrition. The company is based in Utrecht, Netherlands and was founded in 2020 by Jeanette Leusen. | Miscellaneous Commercial Services | Director/Board Member | |
Dualyx NV
 Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer | |
Complement Therapeutics Ltd.
 Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
TigaTx, Inc.
 TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Biotechnology | Director/Board Member | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer |
Statistik
International
| Niederlande | 32 |
| Vereinigte Staaten | 7 |
| Vereinigtes Königreich | 6 |
| Belgien | 4 |
| Deutschland | 4 |
Sektoral
| Health Technology | 23 |
| Commercial Services | 12 |
| Consumer Services | 9 |
| Electronic Technology | 2 |
| Finance | 2 |
Operativ
| Director/Board Member | 161 |
| Corporate Officer/Principal | 50 |
| Chairman | 38 |
| Chief Executive Officer | 36 |
| Private Equity Investor | 20 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| James Gale | 45 |
| Jan Hendrik Egberts | 33 |
| René Kuijten | 30 |
| Alastair Riddell | 24 |
| J. Stellingsma | 21 |
| Edward van Wezel | 20 |
| Simon Sturge | 20 |
| Mark de Boer | 19 |
| Alexander Vos | 15 |
| Philip L. Smith | 12 |
| Frans Emil Eelkman Rooda | 11 |
| Rob de Ree | 9 |
| Hans C. H. L. Pauli | 8 |
| Oskar Slotboom | 8 |
| Daniela Couto | 7 |
- Börse
- Insiders
- Joost J. M. Holthuis
- Unternehmensverbindungen